Skip to main content

Table 1 Baseline characteristics of the study population

From: Effect of type 2 diabetes on coronary artery ectasia: smaller lesion diameter and shorter lesion length but similar adverse cardiovascular events

  Non-DM group DM2 group P
Patients no. 870 258  
Male 743 (85.4) 208 (80.6) 0.079
Age, years 56.40 ± 11.24 59.80 ± 9.72 < 0.001
Height, cm 170.00 [166.00, 175.00] 170.00 [164.00, 175.00] 0.119
Weight, kg 76.00 [69.00, 85.00] 77.00 [68.25, 85.00] 0.881
BMI 26.33 [24.22, 28.73] 27.01 [24.52, 29.38] 0.093
Clinical presence (%) 0.037
 Asymptomatic 18 (2.1) 6 (2.3)  
 Stable angina 278 (32.0) 90 (34.9)  
 Unstable angina 384 (44.1) 125 (48.4)  
 NSTEMI 54 (6.2) 13 (5.0)  
 STEMI 122 (14.0) 19 (7.4)  
 Dyspnea 7 (0.8) 0 (0.0)  
 Palpitation 7 (0.8) 5 (1.9)  
Acute MI 176 (20.2) 32 (12.4) 0.006
Prior MI 244 (28.0) 66 (25.6) 0.484
Prior PCI 203 (23.3) 71 (27.5) 0.196
Hypertension 555 (63.8) 182 (70.5) 0.054
Dyslipidemia 536 (61.6) 183 (70.9) 0.008
Peripheral arterial disease 60 (6.9) 21 (8.1) 0.588
Family history of CAD 145 (16.7) 44 (17.1) 0.959
Current smoker 306 (35.2) 88 (34.1) 0.810
LVEF 62.00 [57.00, 66.20] 62.05 [58.02, 66.10] 0.417
LVID 50.00 [47.00, 53.00] 50.00 [46.00, 53.00] 0.461
HbA1c 5.90 [5.60, 6.10] 7.30 [6.50, 8.10] < 0.001
Cr 78.30 [69.14, 88.50] 76.10 [67.14, 86.06] 0.041
EGFR 114.10 ± 25.51 114.49 ± 28.33 0.832
HsCRP 1.91 [0.98, 4.29] 1.91 [1.09, 4.38] 0.531
TC 4.23 [3.56, 5.00] 4.05 [3.41, 4.72] 0.015
TG 1.58 [1.14, 2.09] 1.70 [1.27, 2.26] 0.006
LDL 2.50 [1.94, 3.16] 2.38 [1.84, 2.94] 0.018
HDL 0.98 [0.85, 1.16] 0.95 [0.79, 1.09] 0.001
NT-proBNP 205.73 [109.25, 269.00] 196.26 [109.25, 238.24] 0.307
Medications at discharge
 Aspirin 843 (96.9) 253 (98.1) 0.437
 Clopidogrel 586 (67.4) 178 (69.0) 0.676
 Ticagrelor 22 (2.5) 6 (2.3) 1.000
 Statins 786 (90.3) 236 (91.5) 0.672
 ACEI/ARB 472 (54.3) 149 (57.8) 0.357
 β-blocker 736 (84.6) 225 (87.2) 0.348
 CCB_DHP 194 (22.3) 81 (31.4) 0.004
 CCB_nonDHP 160 (18.4) 53 (20.5) 0.493
 Nitrates 730 (83.9) 227 (88.0) 0.132
Revascularization (%) 1.000
 None 361 (41.5) 107 (41.5)
 PCI 377 (43.3) 112 (43.4)
 CABG 132 (15.2) 39 (15.1)
Duration of diabetes diagnosis, years 6.00 [2.00, 10.00]
Glucose-lowering treatment before admission 213 (82.56)
 Insulin 89 (34.50)
 Metformin 68 (26.36)
 α-glucosidase 95 (36.82)
 Sulfonylurea 46 (17.83)
 Thiazolidinedione 4 (1.55)
 Glinides 19 (7.36)
 DPP-4 inhibitor 3 (1.16)
 GLP-1RA 0 (0.00)
Glucose-lowering treatment at discharge 228 (83.37)
 Insulin 96 (37.21)
 Metformin 78 (30.23)
 α-glucosidase 115 (44.57)
 Sulfonylurea 49 (18.99)
 Thiazolidinedione 4 (1.55)
 Glinides 18 (6.98)
 DPP-4 inhibitor 5 (1.94)
 GLP-1RA 2 (0.78)
  1. Values are mean  ±  SD, n (%), or median (interquartile range) unless otherwise stated
  2. ACEI angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blockers; BMI body mass index; CABG coronary artery bypass grafting; CAD coronary artery disease; DHP dihydropyridine; DPP-4 dipeptidyl peptidase-4; EGFR estimated glomerular filtration rate; GLP-1RA glucagon-like peptide-1 receptor agonist; HsCRP high sensitivity C-reactive protein; LVEF left ventricular ejection fraction; LVID left ventricular internal dimension; MI myocardial infarction; NSTEMI non–ST-segment elevation myocardial infarction; PCI percutaneous coronary intervention; STEMI ST-segment elevation myocardial infarction